Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jul 18;7(1):95.
doi: 10.1186/s13643-018-0761-2.

Cannabis for pediatric epilepsy: protocol for a living systematic review

Jesse Elliott  1   2 , Deirdre DeJean  3 , Tammy Clifford  4   5 , Doug Coyle  4 , Beth Potter  4 , Becky Skidmore  6 , Christine Alexander  6 , Alexander E Repetski  7 , Bláthnaid McCoy  8   9 , George A Wells  4   10
Affiliations

Cannabis for pediatric epilepsy: protocol for a living systematic review

Jesse Elliott et al. Syst Rev. .

Abstract

Background: Pediatric epilepsy, including treatment-resistant forms, has a major effect on the quality of life, morbidity, and mortality of affected children. Interest has been growing in the use of medical cannabis as a treatment for pediatric epilepsy, yet there has been no comprehensive review of the benefits and harms of cannabis use in this population. In this systematic review, we will search for, synthesize, and assess the published and gray literature in order to provide usable and relevant information to parents, clinicians, and policy makers.

Methods: We will perform a living systematic review of studies involving the use of cannabis to treat pediatric epilepsy. We will search the published and gray literature for studies involving children with any type of epilepsy taking any form of cannabis. Studies will be selected for inclusion by two independent reviewers. The primary outcome is seizure freedom. Secondary outcomes are seizure frequency, quality of life (child, caregiver), quality and quantity of sleep, status epilepticus, tonic-clonic seizures, death (all-cause, sudden unexpected death in epilepsy), gastrointestinal adverse events (diarrhea, vomiting), and visits to the emergency room. The quality of each included study will be assessed. If data are sufficient in quantity and sufficiently similar, we will conduct pairwise random-effects meta-analysis. We will repeat the literature search every 6 months to identify studies published after the previous search date. Sequential meta-analysis will be performed as necessary to update the review findings.

Discussion: Our review aims to provide a comprehensive and up-to-date summary of the available evidence to inform decisions about the use of cannabis in children with treatment-resistant epilepsy. The results of this review will be of use to parents, clinicians, and policy makers as they navigate this rapidly evolving area.

Systematic review registration: PROSPERO CRD42018084755.

Keywords: Cannabidiol; Cannabinoids; Cannabis; Efficacy; Living systematic review; Meta-analysis; Pediatric epilepsy; Safety; Seizure.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

Bláthnaid McCoy is the principal investigator in a study of cannabinoids for Dravet syndrome. Alexander Repetski is a director of communications at a licensed cannabis producer. The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

    1. O’Connell BK, Gloss D, Devinsk O. Cannabinoids in treatment-resistant epilepsy: a review. Epilepsy Behav. 2016;70:341–348. doi: 10.1016/j.yebeh.2016.11.012. - DOI - PubMed
    1. McCall C. Momentum grows for medical use of cannabis. Lancet. 2015;386:1615–1616. doi: 10.1016/S0140-6736(15)00674-1. - DOI - PubMed
    1. Porter BE, Jacobson C. Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy. Epilepsy Behav. 2013;29:574–577. doi: 10.1016/j.yebeh.2013.08.037. - DOI - PMC - PubMed
    1. Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Hauser WA, Mathern G, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010;51:1069–1077. doi: 10.1111/j.1528-1167.2009.02397.x. - DOI - PubMed
    1. Téllez-Zenteno JF, Hernández-Ronquillo L, Buckley S, Zahagun R, Rizvi S. A validation of the new definition of drug-resistant epilepsy by the International League Against Epilepsy. Epilepsia. 2014;55:829–834. doi: 10.1111/epi.12633. - DOI - PubMed

Publication types